Vorinostat: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Vorinostat. Educational only — not medical advice.
Labeled uses
ZOLINZA ® is indicated for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma who have progressive, persistent or recurrent disease on or following two systemic therapies.
Source: FDA labeling via NIH DailyMed (set cd86ee78…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.